ArticleBioinformatics advances2026
pLM-SAV: a Δ-embedding approach for predicting pathogenic single amino acid variants.
Article in Bioinformatics advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Motivation: Predicting whether single amino acid variants (SAVs) in proteins lead to pathogenic outcomes is a critical challenge in molecular biology and precision medicine. Experimental determination of all possible mutation effects is infeasible, and while state-of-the-art tools such as AlphaMissense show promise, their diagnostic performance is insufficient and they are often difficult to run locally. Results: We developed pLM-SAV, a simple yet effective predictor that leverages protein language models (pLMs). Δ-embeddings, computed as the difference between wild-type and mutant sequence embeddings, are used as input for a convolutional neural network. We trained our model on a well-characterized, labelled set of Eff10k and evaluated it on a non-homologous subset of ClinVar data. This approach performs exceptionally well on the Eff10k test folds and reasonably on ClinVar test sets. On ambiguity-defined subsets, pLM-SAV provides complementary predictions to AlphaMissense and REVEL, although these methods retain higher overall performance on broad ClinVar benchmarks. Our results show that a compact predictor trained on labelled variant-effect data can provide useful predictive performance across multiple benchmarks. Unlike previous methods such as VESPA, pLM-SAV uses no handcrafted features or substitution matrices, relying solely on pLM-derived representations. Δ-embedding-based features may provide useful additional signals for future mutation-effect predictors or integrative models. Availability and implementation: The code is available at https://doi.org/10.5281/zenodo.15502498.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.